Biotech Values

[DewDiligence]

It’s notable that Cipro is a comparator, but I would not call it odd insofar as the phototoxicity trial is in healthy volunteers. If the trial were being conducted in HCV patients, a Cipro comparator arm would indeed be odd!

I wonder if J&J really feels strongly about this compound or if they just don't have anything else far enough along (aside from their Vertex x-US deal).

JNJ rarely, if ever, talks about TMC435 during investor presentations. Draw you own conclusions :- )